

Attorney's Docket No. 002019-678

Patent
CENTER 1600/2900

DEC 17 2001

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Konradi, et al.

Application No.: 09/909,838

Filed: July 20, 2001

For: Beta-Amino Acid Derivatives-Inhibitors of
Leukocyte Adhesion Mediated by VLA-4

Group Art Unit: 1614

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.


- ☒ [x] No additional fee for submission of an IDS is required.
- ☐ [] The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ [] A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ [] Charge \$ _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ [] A check in the amount of \$ _____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

By: 
Gerald F. Swiss
Registration No. 30,113

Date: November 20, 2001

RECEIVED

DEC 17 2001

TECH CENTER 1600/2900



Attorney's Docket No. 002010-88

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
)
Konradi et al.) Group Art Unit: 1614
)
Application No.: 09/909,838) Examiner: Unassigned
)
Filed: July 20, 2001)
)
For: Beta-Amino Acid Derivatives-Inhibitors of)
Leukocyte Adhesion Mediated by VLA-4)
)
)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

U.S. Patents:

Kogan, et al., *U.S. Patent No. 5,510,332*, issued April 23, 1996

Foreign Patents:

Hemler and Takada, *European Patent Application Publication No. 330,506*, published August 30, 1989.

International Patent Appl. Publication No. WO 96/01644

Articles:

Abraham, et al., *J. Clin. Invest.*, 93:776 (1994)

Bao, et al., *Diff.*, 52:239 (1993)

Baron, et al., *J. Clin. Invest.*, 93:1700 (1994)

Baron, et al., *J. Exp. Med.*, 177:57 (1993)

RECEIVED

DEC 17 2001

TECH CENTER
300/2900

Information Disclosure Statement
Application No. 09/909,838
Attorney's Docket No. 0020102678

Page 2

- Burkly, et al., *Diabetes*, 43:529 (1994)
- Cybulsky, et al., *Science*, 251:788 (1991)
- Elices, et al., *Cell*, 60:577-584 (1990)
- Elices, et al., *J. Clin. Invest.*, 93:405 (1994)
- Hamann, et al., *J. Immunology*, 152:3238 (1994)
- Kawaguchi, et al., *Japanese J. Cancer Res.*, 83:1304 (1992)
- Lauri, et al., *British J. Cancer*, 68:862 (1993)
- Li, et al., *Arterioscler. Thromb.*, 13:197 (1993)
- Mulligan, et al., *J. Immunology*, 150:2407 (1993)
- Okarhara, et al., *Can. Res.*, 54:3233 (1994)
- Osborn, *Cell*, 62:3-6 (1990)
- Paavonen, et al., *Int. J. Can.*, 58:298 (1994)
- Paul, et al., *Transpl. Proceed.*, 25:813 (1993)
- Postigo, et al., *J. Clin. Invest.*, 89:1445 (1991)
- Pretolani, et al., *J. Exp. Med.*, 180:795 (1994)
- Sasseville, et al., *Am. J. Path.*, 144:27 (1994)
- Schadendorf, et al., *J. Path.*, 170:429 (1993)
- Springer, *Nature*, 346:425-434 (1990)
- van Dinther-Janssen, et al., *J. Immunology*, 147:4207 (1991)
- van Dinther-Janssen, et al., *Annals. Rheumatic Dis.*, 52:672 (1993)
- Vedder, et al., *Surgery*, 106:509 (1989)

Yang, et al., *Proc. Nat. Acad. Science (USA)*, 90:10494 (1993)


Yednock, et al., *Nature*, 356:63 (1992)

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Gerald F. Swiss
Registration No. 30,113

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650) 622-2300

Date: November 20, 2001